Induction of autophagy in rats upon overexpression of wild-type and mutant optineurin gene by Hongyu Ying et al.
Ying et al. BMC Cell Biology  (2015) 16:14 
DOI 10.1186/s12860-015-0060-xRESEARCH ARTICLE Open AccessInduction of autophagy in rats upon
overexpression of wild-type and mutant
optineurin gene
Hongyu Ying1*, Sanja Turturro1, Tara Nguyen1, Xiang Shen1, Ruth Zelkha1, Elaine C Johnson2, John C Morrison2
and Beatrice YJT Yue1*Abstract
Background: Optineurin is a gene associated with normal tension glaucoma and amyotrophic lateral sclerosis. It has
been reported previously that in cultured RGC5 cells, the turnover of endogenous optineurin involves mainly the
ubiquitin-proteasome pathway (UPP). When optineurin is upregulated or mutated, the UPP function is compromised as
evidenced by a decreased proteasome β5 subunit (PSMB5) level and autophagy is induced for clearance of the optineurin
protein.
Results: Adeno-associated type 2 viral (AAV2) vectors for green fluorescence protein (GFP) only, GFP-tagged
wild-type and Glu50Lys (E50K) mutated optineurin were intravitreally injected into rats for expression in retinal
ganglion cells (RGCs). Following intravitreal injections, eyes that received optineurin vectors exhibited retinal
thinning, as well as RGC and axonal loss compared to GFP controls. By immunostaining and Western blotting,
the level of PSMB5 and autophagic substrate degradation marker p62 was reduced, and the level of autophagic
marker microtubule associated protein 1 light chain 3 (LC3) was enhanced. The UPP impairment and autophagy
induction evidently occurred in vivo as in vitro. The optineurin level, RGC and axonal counts, and apoptosis in
AAV2-E50K-GFP-injected rat eyes were averted to closer to normal limits after treatment with rapamycin, an
autophagic enhancer.
Conclusions: The UPP function was reduced and autophagy was induced when wild-type and E50K optineurin
was overexpressed in rat eyes. This study validates the in vitro findings, confirming that UPP impairment and
autophagy induction also occur in vivo. In addition, rapamycin is demonstrated to clear the accumulated
mutant optineurin. This agent may potentially be useful for rescuing of the adverse optineurin phenotypes
in vivo.
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Glaucoma is one of the leading causes of irreversible bi-
lateral blindness worldwide. Optineurin or the “optic
neuropathy inducing” gene was discovered in 2002 [1] to
be a candidate gene of primary open-angle glaucoma
(POAG), the most common form of glaucoma. POAG,
characterized by degeneration of retinal ganglion cells* Correspondence: hying@uic.edu; beatyue@uic.edu
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unless otherwise stated.(RGCs) and progressive axonal and visual field loss, is
age-related and frequently associated with increased in-
traocular pressure (IOP) [2]. It is genetically heteroge-
neous, caused by several susceptibility genes [3-5] as
well as environmental factors [5]. Optineurin was found
to be linked in particular to normal tension glaucoma
(NTG) [3,6], a subtype of POAG. Optineurin mutations
were noted to vary with ethnic background [7]. The
Glu50Lys (E50K) mutation, found in Caucasian and His-
panic populations, seems to be associated with a more
progressive and severe disease in NTG patients [8].is is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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reported to associate with amyotrophic lateral sclerosis
(ALS) [9,10]. In addition, optineurin was identified as
one of the genetic risk factors for Paget’s disease of bone
[11,12].
The human optineurin gene codes for a 577-amino
acid protein [1]. The optineurin protein consists of a
NF-κB essential molecule (NEMO)-like domain, leucine
zipper motif, multiple coiled-coil motifs, an ubiquitin
binding domain, a microtubule associated protein 1 light
chain 3 (LC3)-interacting motif, and a carboxyl (C)-ter-
minal zinc finger [13]. Optineurin is a cytosolic protein
that is not secreted [14]. It is expressed in many non-
ocular tissues such as the brain and the heart as well as
in ocular tissues including the retina and the trabecular
meshwork [13,15].
Optineurin has been shown to be a negative regulator
of the NF-κB pathway [16-20], an autophagy receptor
[21-23], as well as a player in antiviral immune response
[24] and mitotic progression [25,26]. This protein is
moreover demonstrated to interact and form complexes
with proteins including Rab8, huntingtin, myosin VI,
and transferrin receptor, and such interactions may be
the basis why optineurin is also involved in regulation of
protein trafficking [27-31].
It has been previously reported that in cultured RGC5
cells, optineurin is ubiquitinated and the turnover of en-
dogenous optineurin involves mainly the ubiquitin prote-
asome pathway (UPP) in normal homeostatic situation
[32]. When optineurin is upregulated or mutated, the
level of proteasome β5 subunit (PSMB5), an indicator of
proteasome activity [33,34], is reduced, signifying a com-
promised UPP function [32]. The level of the lipidated
form of LC3, LC3-II, is elevated, indicating that autopha-
gosome formation/autophagy is increased [35]. Addition-
ally, the level of p62, a maker for autophagy substrate
degradation [35-37], was concurrently found declined in
E50K optineurin-transfected RGC5 cells [Ying and Yue,
unpublished observations submitted for publication],
suggesting an activation of both autophagy and autopha-
gic flux.
To validate the in vitro results and substantiate their
relevance, especially in light of the recent finding that
the originally thought rat retinal ganglion RGC5 cell line
is in fact 661 W [38], a mouse SV-40 T antigen trans-
formed photoreceptor cell line, the present in vivo inves-
tigation was undertaken. Adeno-associated type 2 viral
(AAV2) vectors for green fluorescence protein (GFP),
GFP-tagged wild-type and E50K optineurin were intravi-
treally injected into rats for expression in RGCs. The
purpose was to determine whether impairment of UPP
and/or induction of autophagy would take place in vivo
as in vitro. Additionally, the study examined whether
the accumulated mutant optineurin could be efficientlycleared by rescuing strategies such as the use of au-
tophagic enhancer rapamycin.
Results
Normal IOP in rAAV transduced eyes
To introduce gene expression in the RGC layer in the ret-
ina, AAV2-GFP-, AAV2-optineurin (OPTN)-GFP-, and
AAV2-E50K-GFP-vectors were injected intravitreally into
the left eyes of Brown Norway rats. The IOP was mo-
nitored at day 0 (before injection), and weeks 2, 4 and
5 post-injection using rebound tonometer TonoLab in
awake rats. No significant changes were observed in any
of the injected eyes compared with PBS-injected or non-
injected controls (Figure 1A). The IOP during the course
of experiments was in general 11–14 mmHg in all of the
rat eyes as expected.
Transgene expression
The efficiency of transgene expression was assessed in
retinal whole mounts. After enucleation of the globe, the
anterior segment was removed and the posterior segment
was fixed briefly. The retina was then isolated, divided
into quadrants and flat mounted onto a microscopic slide
with the RGC side up. The GFP-positive cells were visu-
alized and the number of GFP positive cells in digital
images of 20 randomly sampled 20x whole mount fields
was determined. Transduction of AAV2-GFP (Figure 1B),
AAV2-OPTN-GFP (Figure 1C) and AAV2-E50K-GFP
(Figure 1D) was found highly and equally efficient in cells
of the RGC layer. The total number of GFP-positive cells
was 105718 ± 9047 per retina in the AAV2-GFP treated
control eyes. The cell count was significantly (P < 0.0062)
reduced to 79838 ± 9368 and 71874 ± 9865/retina re-
spectively in AAV2-OPTN-GFP- and AAV2-E50K-GFP-
injected eyes (Figure 1E).
Degeneration of optic nerve axons in optineurin
transduced eyes
To examine the optic nerve axons, optic nerves in the enu-
cleated eyes were fixed and processed. Semi-thin sections
prepared were stained with toluidine blue. Subsequent ana-
lysis of the optic nerve axons using high-power light mi-
croscopy demonstrated normal axonal features in AAV2-
GFP-treated and PBS-injected control eyes. By contrast,
densely stained degenerating axons as well as axonal swell-
ings were observed, interspersed with normal axons, in eyes
administered with optineurin and E50K viral constructs
(Figure 2A). Quantification of axonal counts indicated a
significantly (P < 0.0042) decreased axon count in AAV2-
OPTN-GFP-injected (540323 ± 54213) eyes compared to
PBS (739059 ± 12434) and GFP (658955 ± 35326) controls.
A greater degree of axon decrease was seen in E50K-
expressing (489696 ± 69261) specimens (Figure 2B).
Figure 1 IOP readings and retinal ganglion cell counts in AAV2 viral vector injected rat eyes. A. IOP measurements. One eye of the rats was
intravitreally injected with one of the AAV2 viral vectors (GFP, green bars; OPTN-GFP or OPTN, yellow bars; E50K-GFP or E50K, orange bars), and
the contralateral eye was either non-injected (white bars) or injected with PBS (gray bars) as negative controls. The IOP was measured before
injection (referred to as day 0), or 2, 4, and 5 weeks post-injection. Results are presented as mean ± SEM (n =15). No IOP difference was seen
between AAV2 injection and control groups. B-D. Retinal whole mounts. Rat eyes were injected intravitreally with one of the AAV2 viral vectors
(GFP, B; OPTN-GFP or OPTN, C; and E50K-GFP or E50K, D). Five weeks post-injection, the retinal whole mounts were visualized by fluorescence
microscopy. Efficient transduction in cells in the retinal ganglion layer was observed. The GFP expression was robust with clearly visible retinal
ganglion axons. Insets show other areas at a higher magnification. Scale bars, 20 μm. E. Bar graphs depict total retinal ganglion cell counts per
retina. Results are presented as mean ± SEM (n = 6). *, P < 0.0062 compared with GFP controls.
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optineurin transduced eyes
Retinal cross sections were prepared for hematoxylin
and eosin (H and E) staining to assess retinal changes inoptineurin transduced rat eyes. It was noted that 5 weeks
following AAV2-OPTN-GFP or AAV2-E50K-GFP injec-
tion, the retina showed a reduced number of ganglion
cells and thinning of the inner nuclear layer compared
Figure 2 Optic nerve axons in AAV2 viral vector injected rat eyes. A. High-power view of representative optic nerve axon cross sections of rats
5 weeks following injection of PBS, or one of the viral vectors (GFP, OPTN-GFP or OPTN, E50K-GFP or E50K). PBS injection was used as negative
control. Magnification, x100. Scale bar, 20 μm. The axons in PBS- and GFP vector-injected eyes showed normal morphology while densely stained
degenerating axons as well as axonal swellings were seen in wild-type OPTN- and E50K-GFP-vector injected eyes. B. Total axon counts. The value
(mean ± SEM) in wild-type OPTN-GFP injected eyes was significantly (P < 0.0042, asterisks, n =15) lower than that in PBS and GFP injected control
eyes. A greater decrease of total axon count was found in E50K-GFP injected eyes.
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as well as non-injected (data not shown) controls.
The expression level of optineurin, p62, PSMB5, and
LC3 in the RGC layer was investigated in retinal cross
sections by immunostaining. As anticipated, retinal sec-
tions from wild-type and E50K optineurin transduced
eyes yielded a stronger optineurin staining than the con-
trols (Figure 3B, top panel). They in addition displayed a
fainter staining of p62 (Figure 3B, second panel) and
PSMB5 (Figure 3B, third panel), and a stronger staining
of LC3 (Figure 3B, bottom panel) in RGCs. Western blot
analyses further revealed that the PSMB5 protein level
was decreased by approximately 50% while the opti-
neurin level (optineurin and GFP-tagged optineurin) was
increased by 8–9 fold upon transduction of wild-type
and E50K optineurin in rat eyes (Figure 3C).
LC3 exists in two forms. LC3-I (18 kDa) is cytosolic and
LC3-II (16 kDa) is the lipidated form (conjugated to phos-
phatidylethanolamine) that inserts into the membrane. The
amount of LC3-II is correlated with the extent of autopha-
gosome formation and increasing levels of LC3-II on im-
munoblots have been used to document induction of
autophagy [35]. In rats, the level of LC3-II protein in the
retina was found increased by approximately 1.6-2.0 fold by
Western blotting in AAV2-optineurin wild-type and E50K-
treated eyes (Figure 3C). p62, an ubiquitin-binding scaffold
protein [36], is itself degraded by autophagy and serves as a
maker for autophagy substrate degradation [35,36]. A de-
creased p62 level has been correlated with activation of au-
tophagy and autophagic flux and an increased p62 level
correlates with autophagic suppression [37]. The observed
weaker p62 staining corroborated an induced autophagyand enhanced autophagic flux in wild-type and E50K opti-
neurin transduced eyes.
Apoptosis level was elevated in RGCs in optineurin
transduced eyes
TdT-Mediated dUTP nick-end labeling (TUNEL) assay
was carried out to assess apoptosis in the RGC layer.
Retinal tissue sections from rats 5 weeks following the
AAV2-OPTN-GFP or AAV2-E50K-GFP injection were
found to exhibit a much higher percentage (6.2 ± 0.4 and
11.7 ± 1.9 respectively) of apoptotic RGCs than AAV2-
GFP (1.4 ± 0.3) and non-injected (0.3 ± 0.02) controls
(Figure 4).
Proteasomal compromise and autophagy induction in rat
eyes with chronic hypertension
Hypertonic saline was injected into episcleral veins of
Brown Norway rat to obstruct the aqueous outflow to
achieve chronic IOP elevation [39,40]. The optic nerve
damage in this rat model was graded from 1 (no injury)
to 5 (active degeneration in the entire optic nerve area)
[39]. In one set of experiment, sections with optic nerve
damage graded as 1, 2.75 (degenerating axons and axonal
swelling spread more than the focal area), and 5 were
used. The sections were deparaffinized and stained in
parallel for optineurin, PSMB5, and LC3. Analogous to
wild-type and E50K optineurin transduced eyes, an
enhanced optineurin, reduced PSMB5 and increased LC3
staining was observed in the RGC layer of sections from
injury grades 2.75 and 5 compared to injury grade 1.0
(normal) in the rat ocular hypertension model (Figure 5A,
left panel). Quantification analyses confirmed that the
Figure 3 Histology and levels of optineurin, p62, PSMB5 and LC3 in
the retina of viral vector injected rat eyes. A. Representative retinal
sections collected following injection of PBS, and GFP-, wild-type
OPTN (OPTN)- and E50K-OPTN (E50K)-GFP vectors were stained with
hematoxylin and eosin (H & E). GCL, ganglion cell layer; IPL, inner
plexiform layer; INL, inner nuclear layer; OPL, outer plexiform layer;
and ONL, outer nuclear layer. The retinal ganglion cell number was
decreased and the INL thickness was reduced in OPTN- and E50K-
injected specimens compared to PBS and GFP controls. Scale bar,
25 μm. B. Retinal sections from rat eyes were stained in parallel with
polyclonal anti-optineurin, p62, PSMB5, or LC3 (all in red). An en-
hanced optineurin (OPTN) and LC3 staining, and a declined PSMB5
and p62 staining were observed in the retinal ganglion layer of OPTN
and E50K-injected eyes compared to controls. Scale bar, 25 μm.
C. Western blotting for optineurin, PSMB5, LC3, and GAPDH in retinal
extracts from GFP-, OPTN-GFP (OPTN)-, and E50K-OPTN-GFP (E50K)-
injected eyes. The LC3-I bands were very faint and only those of LC3-
II were shown. The level of optineurin overexpression was estimated
by comparing the intensities of both (optineurin-GFP + optineurin)
bands from optineurin treatment groups to those of the endogenous
optineurin band from GFP groups (all were normalized against
GAPDH). The optineurin/GAPDH ratios (n = 3) for the GFP, OPTN, and
E50K groups were, respectively, 1.0 ± 0.2, 9.5 ± 0.3, and 8.0 ± 0.5. For
PSMB5/GAPDH, the corresponding values (relative to the first GFP
sample) were 1.1 ± 0.1, 0.5 ± 0.1, and 0.5 ± 0.1; and for LC3/GAPDH,
they were 1.0 ± 0.1, 1.6 ± 0.2, and 2.1 ± 0.2. All OPTN and E50K results
were significantly (P < 0.0015) different from those of GFP controls.
Figure 4 Apoptosis of cells in the retinal ganglion layer of rat eyes.
A. Apoptotic cells in the retinal ganglion layer in eyes non-injected
(Normal), and those 5 weeks post-injected with GFP, OPTN-GFP
(OPTN), and E50K-GFP (E50K) viral vectors. A representative image
from each group was shown. Retinal sections were examined by
an ApopTag kit. Images (20 of 10× fields) were captured and cell
counting was performed to determine the total number of retinal
ganglion cells (RGCs) and the number of apoptotic ones (pink). Scale
bar, 25 μm. B. Percentage of apoptotic RGCs was calculated. Results
are shown in mean ± SEM (n = 10). The values for normal control,
and GFP, OPTN, and E50K groups were, respectively, 0.3 ± 0.02,
1.4 ± 0.3, 6.2 ± 0.4, and 11.7 ± 1.9. *, P < 0.0005 compared with
non-injected normal and GFP controls.
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and the PSMB5 level was lower with advanced optic
nerve injury. The alterations were more notable with in-
creasing injury grades (Figure 5A, right panel). In another
set of experiment, sections with optic nerve damage
graded as 1, 2.6 to 3.0, and 5 were stained. An increased
optineurin and LC3 staining and a decreased PSMB5
staining, were likewise discerned especially with grade 5
optic nerve damage (Figure 5B). These results suggested
that an inhibition of proteasomal activity and induction of
autophagy might also occur in hypertensive eyes in the rat
experimental model.
Figure 5 Immunostaining of optineurin (OPTN), PSMB5, and LC3 in the eyes of a rat chronic hypertension model. The optic nerve damage in the
rats was graded from 1 (no injury) to 5 (active degeneration in the entire optic nerve area). A. Retinal cross sections of grades 1, 2.75, and 5 were
immunostained. The grade 2.75 and 5 slides showed stronger OPTN and LC3, but weaker PSMB5, staining, compared with that of grading 1.0 (left
panel). Higher magnification of staining was shown in insets. Scale bars, 25 μm. Images (20 of 10× fields) were captured and the intensity of each
staining in retinal ganglion cells was quantified. Results (mean ± SEM, averaged from 40 cells total) are presented in the bar graph at the right
panel. The staining intensity (relative to no injury control grade 1) for optineurin was 1.0 ± 0.04, 1.22 ± 0.04, and 1.36 ± 0.03, respectively, for grades
1, 2.75, and 5. The corresponding relative intensity for PSMB5 was 1.0 ± 0.03, 0.76 ± 0.04, and 0.66 ± 0.04; and that for LC3 was 1.0 ± 0.04, 1.20 ± 0.04
and 1.26 ± 0.03. B. Bar graphs depict the staining intensity of OPTN, PSMB5, and LC3 in retinal ganglion cells in another set of experiments. The
retinal cross sections of grades 1.0, 2.58, 2.75, 3.0, and 5.0 were used. The relative staining intensity (mean ± SEM, averaged from 18–31 cells) for
optineurin was 1.0 ± 0.02, 1.30 ± 0.03, and 1.43 ± 0.01, respectively, for grades 1, 2.6-3.0, and 5. The corresponding intensity for PSMB5 was 1.0 ± 0.04,
0.88 ± 0.02, and 0.86 ± 0.01; and that for LC3 was 1.0 ± 0.02, 1.13 ± 0.04, and 1.38 ± 0.05. **, P < 0.002; *, P < 0.032 compared to grade 1.
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Rapamycin is an inhibitor of the Ser/Thr protein kinase
named “mammalian target of rapamycin” (mTOR) [41].
Inhibition of mTOR mimics cellular starvation that in-
duces autophagy by blocking signals required for cell
growth and proliferation. Rapamycin is thus also recog-
nized as an autophagic inducer. Rats injected with AAV2-
GFP- and AAV2-E50K-GFP-vectors were treated with
rapamycin to determine whether this treatment can re-
duce or rescue optineurin-mediated phenotypes in rats.
Right after intravitreal injection of viral vectors, the treat-
ment began by intraperitoneal injection of 1% v/w solution
of rapamycin, 20 mg/kg body weight, as was successfully
done previously in mouse studies [42]. The IOP, moni-
tored at day 0, and 2, 4, and 5 weeks after viral injection,
was not affected by rapamycin injections (Figure 6A).
Results also indicated that following rapamycin treat-
ments, the RGC (Figure 6B) and axonal (Figure 6C, rightpanel) counts in E50K-GFP-expressing eyes were in-
creased, closer to the control level, compared to the
E50K-without rapamycin treatment group. The RGC
counts were 105105 ± 12750, 104323 ± 20113, 70633 ±
10543, and 82596 ± 11325, and the total axon counts
were 739059 ± 12434, 80642 ± 16413, 540323 ± 46416,
and 732678 ± 25307, respectively, for GFP, GFP + Rapa-
mycin, E50K, and E50K + Rapamycin groups. The optic
nerve axons of GFP control without and with rapamy-
cin treatment groups displayed normal morphology.
E50K-GFP-injected eyes showed a reasonably normal-
appearing optic nerve cross section with rapamycin
treatment, compared with the extensive degeneration
without the treatment (Figure 6C, left panel). The extent
of apoptosis (Figure 6D) was significantly (P = 0.0003)
decreased. The apoptotic percentage was 1.4 ± 0.3, 1.7 ±
0.5, 11.7 ± 1.9, and 2.9 ± 0.3, respectively for GFP, GFP +
Rapamycin, E50K, and E50K +Rapamycin groups.
Figure 6 (See legend on next page.)
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Figure 6 Effects of rapamycin. A. IOP values in rat eyes treated or untreated with rapamycin. Two sets of rats were injected with GFP (green and
blue bars) or E50K-GFP (orange and yellow bars) viral vector. One set (blue and yellow bars) received intraperitoneal injection of rapamycin. The
other set did not receive rapamycin treatment as controls. No change in IOP was observed without or with rapamycin treatment. B. Bar graphs
depict total retinal ganglion cell counts per retina in retinal whole mounts from GFP or E50K-GFP viral vector injected eyes. One set of the animals
received rapamycin treatment. Results are presented as mean ± SEM (n = 4 for GFP and n = 10 for E50K groups). C. Representative high-power
view (100x) of optic nerve axon cross sections from eyes collected 5 weeks following intravitreal injection of GFP or E50K-GFP viral vector without
or with treatment of rapamycin (left panel). Scale bar, 20 μm. Total axon counts in different groups are shown in the bar graph (right panel).
D. Percentage of apoptotic cells in the retinal ganglion cell layer (left panel) in sections from GFP or E50K-GFP viral vector injected eyes without
or with rapamycin (GFP + Rapamycin or GFP + Rapa, E50K + Rapamycin or E50K + Rapa) treatment. E. Immunostaining of optineurin (OPTN), p62,
PSMB5, and LC3 (in red) in GFP and E50K-GFP injected eyes without or with rapamycin treatment. Scale bar, 25 μm. F. Bar graph depicts the
staining intensity (mean ± SEM, n ≥ 3) of OPTN, p62, PSMB5, and LC3 in retinal ganglion cell layer in each treatment group relative to that of the
GFP control group. *, P < 0.015; #, P < 0.05 compared to GFP no treatment controls.
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neurin and LC3 were significantly (p < 0.015) higher, and
those of PSMB5 and p62 were lower, confirming that the
proteasome function was compromised and autophagic
process was activated in E50K transduced rat eyes. Rapa-
mycin treatment in those rats caused a substantial re-
duction in the optineurin level (Figure 6E and F) while
the LC3 level was further elevated (Figure 6E and F). In
GFP viral vector injected specimens, the level of opti-
neurin was similar with or without rapamycin adminis-
tration (Figure 6E and F). Consistent with the rapamycin
autophagy-inducing action, the LC3 staining was en-
hanced and the p62 staining was decreased in the GFP +
Rapamycin group (Figure 6E and F). The level of PSMB5
was also diminished by rapamycin (Figure 6E and F),
which has been reported previously to inhibit proteasome
activity in rapamycin-fed mice [43].
Discussion
Optineurin is a gene linked to NTG and ALS. It has pre-
viously been shown in cultured RGC5 cells that opti-
neurin is ubiquitinated [32]. In normal homeostatic
situation, the endogenous optineurin is processed mainly
through the UPP pathway. Upon overexpression and/or
mutation, the UPP function is inhibited and autophagy
is induced for clearance of the protein [32].
The present study used AAV infection to extend the
in vitro findings to in vivo adult rats. To date AAV has
been the method of choice for gene delivery to RGCs
[44-47]. Little or no signs of inflammation, cytotoxicity,
abnormal growth, or immune reaction have been de-
tected in the eyes following administration of AAVs [46].
There are many different serotypes of AAV, but AAV2
displays excellent tropism for RGCs, especially when
injected into the vitreous [48]. Strong, constitutive pro-
moters such as CMV and/or β-actin are commonly used
to drive transgene expression [44,45,47].
We used pTR-SB-smCBA-V2 vector to construct
AAV2-OPTN-GFP vectors. The advantage of using this
plasmid is that the size of the smCBA promoter is
smaller (approximately 1 kb) compared to the full-lengthCBA (about 1.7 kb), while it still exhibits an expression
pattern similar to that of the full-length CBA in the ret-
ina [49]. Because of the smaller size, wild-type or E50K
mutant OPTN-GFP fusion gene (about 2.5 kb) can be
successfully packaged into viral particles.
In pilot experiments, moderate to strong GFP expres-
sion in RGCs was observed in rat eyes 5 weeks after a
single intravitreal injection of AAV2-GFP containing a
total of 5 × 1010 vp while little inflammation, cytotox-
icity, or abnormal growth was noted. These parameters
were thus selected for the study. The number of GFP-
expressing green cells/field, the average intensity/cell,
the total number of RGCs, and the integrity of optic
nerve axons were compared between the AAV2-GFP
injected eyes and non-injected or PBS-injected controls.
As anticipated from reported observations [46], no sig-
nificant difference was detected. By contrast, in wild-
type and E50K optineurin-injected eyes, the retina was
thinner, the RGC density was lower, the apoptosis level
was higher, the axons were degenerated, and the axon
counts were much reduced. These findings were consist-
ent with the previous in vitro data, which showed that up-
regulated and mutated optineurin induced toxic effects
such as apoptosis [50-53]. Also as in vitro [13,28,31,50,53],
the deleterious optineurin phenotypes were more dra-
matically seen in vivo with the E50K mutation than
the wild-type (Figures 1E, 2 and 4), suggesting that the
observed consequences were, at least in part, related
to the mutant, not merely a reflection of the overex-
pressed protein level. Of note in addition is that dur-
ing the course of the experiment, the IOP in rats after
viral delivery of the optineurin gene to RGCs, as ex-
pected from the clinical perspective, was not increased.
The previous in vitro findings were established using
mostly RGC5 cells, an immortalized rat RGC cell line
created originally by transforming postnatal day 1 rat
retinal cells with E1A adenovirus [54,55]. These cells,
while having been used extensively in the field, are now
shown to be a different retinal cell type, namely, mouse
SV-40 T antigen transformed photoreceptor 661 W cells
[38]. It is thus imperative to validate the results in
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rat eyes, viral expression of wild-type and E50K opti-
neurin in RGC layer did result in a declined PSMB5, an
increased LC3, as well as a reduced p62 levels in the
RGC layer, confirming that an impaired UPP function
and induced autophagic process previously documented
in RGC5 cultures ([32] and unpublished observations)
also occurred in vivo.
Interestingly, in a chronic ocular hypertension rat model
[39,40], a downregulation of the proteasomal activity in
the RGC layer was also observed by PSMB5 immuno-
staining in eyes with optic nerve injuries (Figure 5). In this
rat model, optineurin was in addition found increased and
autophagy was activated in advanced injury (Figure 5).
Optineurin expression has been shown to be upregulated
with sustained pressure elevation in human perfusion
organ cultures [56,57]. Autophagy has also been demon-
strated to be activated in RGCs in other models after optic
nerve transection and ischemia and with acute or chronic
IOP elevation in rats [58-60].
Autophagy has emerged as a key process with implica-
tions in disease conditions such as cancer and neurode-
generative diseases. It is a major degradation pathway
for aggregate-prone, intracytosolic proteins causing neu-
rodegenerative disorders such as Huntington’s disease
[61]. Upregulating autophagy has been shown to be a
promising therapeutic intervention for clearing these
disease-causing proteins [61]. Rapamycin, a compound
already approved by the U.S. Food and Drug administra-
tion [62], and its analogs have been used previously to
reduce huntingtin levels and attenuate the mutant hun-
tingtin toxicity in cell, fly and mouse models of disease
[42]. While rapamycin may also affect pathways other
than autophagy [63,64], its protective effect was attrib-
uted, at least partially, to enhanced clearance of the
mutant protein via autophagy. Rapamycin, lithium, and
trehalose have also been shown to increase clearance of
autophagy substrates α-synuclein and mutant huntingtin
[65,66]. We applied a similar strategy and found that
rapamycin was effective to reduce the overexpressed
E50K optineurin, avert the optineurin phenotype, and
increase cell survival in our in vivo rat model. Currently,
investigators are actively searching for small and safe
molecules to enhance autophagy [67,68]. Reduction of
the optineurin level and rescue of RGCs from cell death
by various approaches in vivo, if successful, will certainly
have high translational impact.
Conclusions
Optineurin is a gene linked to NTG and ALS. It has been
shown previously in cultured RGC5 cells that optineurin
is ubiquitinated. In normal homeostatic situation, the en-
dogenous optineurin is processed mainly through the
UPP pathway. Upon overexpression and/or mutation, theUPP function is compromised and autophagy is induced
for clearance of the protein. We herein demonstrated
that in rat eyes, viral expression of wild-type and E50K
optineurin in RGC layer also resulted in an impaired
UPP function and an induced autophagic process. The
level of PSMB5 and p62 was declined and LC3 was ele-
vated in vivo, confirming the previous RGC5 in vitro
results. Apoptosis was in addition observed. Further-
more, rapamycin was found effective in reducing the
overexpressed E50K optineurin, averting the optineurin
phenotype, and increasing cell survival in the in vivo rat
model. Reduction of the optineurin level and rescue of
RGCs from cell death by rapamycin and other analogs
may have high translational impact.
Methods
Construction of serotype 2 AAV vectors
AAV vector plasmid psmCBA-OPTNWT-EGFP or psmCBA-
OPTNE50K-EGFP was constructed by inserting human
OPTNWT-EGFP or OPTNE50K-EGFP fusion gene into
empty vector pTR-SB-smCBA-V2 (generously provided
by Dr. Sanford L. Boye of University of Florida) which
contains a ubiquitous smCBA promoter (small CMVie
enhancer and chicken β-actin hybrid promoter). Briefly,
OPTNWT-EGFP or OPTNE50K-EGFP was digested with
XhoI and NotI from plasmid pOPTNWT-EGFP or pOPT-
NE50K-EGFP and ligated into XhoI and NotI digested vec-
tor pTR-SB-smCBA-V2. Control vector plasmid psmCBA-
EGFP was additionally made using a similar strategy.
AAV2 vectors were packaged according to previously pub-
lished methods [69] (packaging service was provided by
Powell Gene Therapy Center of University of Florida).
Viral particles were resuspended in phosphate buffered
saline (PBS) (Sigma, St. Louis, MO, U.S.A.) and the titer
was determined by dot blot assays. The resulting titers
were 1.37 × 1013 vg/ml, 2.00 × 1013 vg/ml and 1.51 × 1013
vg/ml for AAV2-smCBA-OPTNWT-EGFP (AAV2-OPTNWT-
GFP), AAV2-smCBA-OPTNE50K-EGFP (AAV2-OPTNE50K-
GFP), and AAV2-smCBA-EGFP (AAV2-GFP) respectively.
Animals
The study was carried out in adult male Brown Norway
rats (170–200 g). All animal procedures were performed
in compliance with the Association for Research in Vi-
sion and Ophthalmology (ARVO) statement for the Use
of Animals in Ophthalmology and Vision Research. The
Brown Norway rat has been a popular research animal
used by various investigators in ophthalmology to create
glaucoma or ocular hypertension models [9,46,70-72].
This animal is mild and not aggressive as other species
and thus can be easily handled [40]. In addition, their
relatively prominent globes and docile nature allow IOP
measurement in the awake state [73]. A total of 78 ani-
mals were used.
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The left eyes of rats were injected with 5 × 1010 vp (2.5
to 3.7 μl) of one of recombinant AAV2 vectors (AAV2-
GFP, AAV2-OPTNWT-GFP or AAV2-OPTNE50K-GFP).
Before intravitreal injection, the eyelids and conjunctival
cul de sac were cleaned and rinsed with 0.5% betadine
solution. Intravitreal injections into the vitreous cham-
ber were performed with a Zeiss operating microscope
under general anesthesia by intraperitoneal injection of
standard rat cocktail consisting of ketamine (100 mg/Kg)
and xylazine (5 mg/Kg), using a 10 μl Hamilton syringe
(Hamilton Company, Reno, NV, U.S.A.) adapted to a
customized pulled glass needle. The contralateral (right)
eyes were injected with PBS, or left non-injected as con-
trols. The sclera was exposed and the tip of the needle
was inserted at a 45° angle through the sclera and retina
into the vitreous space. The solution was injected slowly
over a period of approximately 1 min [73]. Each dosage
was split and injected into two different locations in the
same eye to ensure even distribution of the virus in the
eye. Care was taken to avoid injury to the lens [3,46].
After gentle withdrawal of the needle, erythromycin
ophthalmic ointment was applied to the injection site.
Post viral vector delivery, the rats were administrated
one subcutaneous injection of buprenorphine (0.1 mg/
Kg) to decrease eye rubbing. The rats were subjected to
non-invasive weekly examination with a slit-lamp while
anesthetized to monitor for accidental lens puncturing
and signs of inflammation. The rats were also examined
weekly with an indirect ophthalmoscope to detect retinal
damage and detachment. Rats with punctured lens or
damaged retina were excluded.Chronic ocular hypertension model
Hypertonic saline (NaCl) was injected into episcleral
veins of one eye of Brown Norway rats to obstruct the
aqueous outflow [39,40] and achieve chronic IOP eleva-
tion. The contralateral eyes were left non-injected as
control. The optic nerve head and retinal vasculature
were assessed [40]. Degenerating axons were character-
ized by axonal swellings and myelin debris [40]. The
optic nerve damage in the rat models was graded from 1
(no injury) to 5 (active degeneration in the entire optic
nerve area) [74].IOP measurements
The IOP was measured at day 0 (before injection), and
weeks 2, 4 and 5 post-injection with rebound tonometer
TonoLab (Icare Finland, Helsinki, Finland) in awake rats.
Ten consecutive readings were taken per eye without
any anesthesia. The highest and lowest values were dis-
carded and the mean IOP was recorded as describedpreviously [73]. The IOP in eyes of all treatment groups
was compared.Transgene expression
Five weeks after intravitreal injection, animals were eutha-
nized by CO2 inhalation. The eyes were enucleated and
the anterior segments were removed. The retinal flat
mount (or whole mount) was prepared for transgene ex-
pression. Briefly, the anterior segment was removed and
the posterior segment was fixed in 4% paraformaldehyde
for 30 min. The retina dissected was further fixed briefly,
and carefully transferred to a microscope slide with the
RGC layer side up. Relieving incisions were made to divide
the retina into quadrants and to allow the retina to flatten.
Under Zeiss confocal microscope (Carl Zeiss, Thornwood,
NY, U.S.A.), the GFP green fluorescence was visualized in
a masked manner. The number of GFP-positive cells was
counted in digital images taken at 20x (0.125 mm2) under
microscope from flat mounts in 20 standard fields in an
equally spaced fashion from the center of the retina to the
periphery in each quadrant [75]. The total number of
green cells in these 20 fields was calculated [76]. Compa-
risons between the AAV2- and AAV2-OPTNWT- and
AAV2-OPTNE50K-GFP-injected groups (n = 15) were
made using ANOVA.Histochemical staining, immunofluorescence and
apoptosis
The retinal flat mounts were further fixed overnight in
4% paraformaldehyde, and the retinas were processed
and embedded in paraffin. Sections (6 μm) were used to
visualize the GFP or optineurin-GFP fluorescence dir-
ectly under a Zeiss fluorescence microscope (Carl Zeiss),
in a masked fashion after AAV2-, AAV2-OPTNWT- and
AAV2-OPTNE50K-GFP injections.
Paraffin sections were also obtained from Brown
Norway rats with chronic IOP elevation [39,40]. For the
first set of immunostaining experiments, sections from rat
eyes (3 each) with optic nerve damage graded as 1, 2.75
(degenerating axons and axonal swelling spread more than
the focal area), and 5 were used. The mean IOP readings
in those eyes were 21.6, 27.2, and 37.2 mmHg, respect-
ively. For the second immunostaining experiments, sec-
tions from rat eyes (n = 4 or 5 each) with 1, 2.6 to 3.0
(2.58, 2.75, 2.75, and 3), and 5 optic nerve injury grades
were used.
The sections were deparaffinized and immunostained
with polyclonal anti-optineurin (1:100, Cat. 100000,
Cayman Chemical, Ann Arbor, MI, U.S.A.) and Cy3-
labeled secondary antibody to yield positive staining
products in red for transgene expression assessments.
The morphology of the retina was examined by H and E
staining. The number of RGCs was also counted.
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PSMB5 (1:100, Cat. Ab3330, Abcam, Cambridge, MA,
U.S.A.), for p62 with anti-p62 (1:1000, Cat. PM045, MBL
International, Woburn, MA, U.S.A.), and for LC3 with
anti-LC3 (1:100, Cat. PD015, MBL International) was
also carried out. Images were acquired using a 20 or 40×
objective on an Axioscope (Carl Zeiss MicroImaging)
with the aid of MetaMorph software (Molecular Devices,
Downingtown, PA, U.S.A.). The staining intensity in the
slides from the chronic ocular hypertension model was
quantified by image analysis on selected images. The
image file was converted from RGB to grey scale and
Imaging Processing Tool kit 3.0 (Reindeer Games, Inc,
Gainesville FL, U.S.A.) was used to measure the intensity
of staining in at least 10 RGCs. Background intensity
taken in empty spaces was subtracted. The staining
intensity in RGCs from injury grade 2.6, 2.75, 3, and 5
slides was compared with that from grade 1 using Stu-
dent’s t tests. Values of P < 0.05 were considered to be
significant.
To examine apoptosis, TUNEL assay using an Apop-
Tag kit from Millipore (Billerica, MA, U.S.A.) was per-
formed. The percentage of apoptotic cells was calculated
(from counts of total and apoptotic cells) in RGC layer
on each specimen from 20 images of 10x fields.
Western blot analysis
Five weeks following injections as described above, rat
eyes were enucleated and placed in PBS. After remov-
ing the anterior portion of the eye and the lens, the
retina was dissected from the eyecup disc and dis-
solved in electrophoresis sample buffer, boiled and
subjected to Western blotting for optineurin, PSMB5
and LC3 levels [32].
Axon counts
The optic nerves in the enucleated eyes were fixed with
2% paraformaldehyde and 2.5% glutaraldehyde in 0.1 M
sodium cacodylate buffer, pH 7.4, post fixed in 1% os-
mium tetroxide for 2 h and in 0.25% uranyl acetate for
an additional 2 h. The nerves were dehydrated with
series of alcohol and propylene oxide, and embedded in
Embed-812 medium (Electron Microscopy Sciences,
Hatfield, PA, U.S.A.). The axons in the optic nerve in rat
eyes (n = 15/treatment group) either injected with PBS,
AAV2-GFP, AAV2-OPTNWT-GFP, or AAV2-OPTNE50K-
GFP were evaluated as described by Quigley and co-
workers [75]. Briefly, semi-thin (0.9 μm) sections were
stained with 1% toluidine blue and imaged with spinning
disk live-cell imaging system (Carl Zeiss) with 10x (for
measurement of area of optic nerve) or 100x (for estima-
tion of axon count) objective. The dark staining myelin
was identified and the myelinated fibers were enumer-
ated [77,78]. The density of axons in high-power fieldsin 10 selected, non-overlapping areas in central, superior,
inferior, temporal, and nasal optic nerve, were deter-
mined by MetaMorph. The total nerve fiber count was
estimated by multiplying density with the area to yield
axon count [70,77]. Counts from all treatment groups
were compared. Statistical differences were evaluated by
ANOVA.
Effects of rapamycin
The eyes of two sets of rats were injected with either
AAV2-GFP (n = 4) or AAV2-OPTNE50K-GFP (n = 10) as
above. Half of each set of animals received rapamycin
(20 mg/Kg body weight) (Sirolimus, LC Lab, Woburn,
MA, U.S.A.) via intraperitoneal injection [42,79] 3 times
a week for 5 weeks. The rats were subsequently sacri-
ficed, and the eyes were enucleated for flat mount, light
microscopy, RGC counts, Western blotting, immuno-
staining for optineurin, p62, PSMB5, LC3, and TUNEL
staining, and total nerve fiber count as described above.
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